Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

NCT ID: NCT05241028

Last Updated: 2023-10-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-01
• Study Completion Date: 2029-02-28

Brief Summary

This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until recurrence of the disease or intolerable toxicity, following complete tumour resection with or without adjuvant standard chemotherapy.

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ensartinib

Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity

Group Type: EXPERIMENTAL

Ensartinib

Intervention Type: DRUG

Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity

Interventions

Ensartinib

Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity

Intervention Type: DRUG

Other Intervention Names

X-396 capsule

Eligibility Criteria

Inclusion Criteria

• Completely resected pathological stage IB-IIIA NSCLC with ALK-fusion positive (confirmed by FISH, IHC or NGS).
• Males or females aged ≥18 years, ≤75 years.
• ECOG performance status 0-2.
• Completely recovered from surgery or standard postoperative chemotherapy before receiving adjuvant ensatinib treatment. (When starting the study treatment, the patient must have recovered from all toxicities greater than CTCAE Grade 1 caused by the previous treatment, except for hair loss and Grade 2 neuropathy related to previous platinum-based treatments).
• Clinical examinations before treatment report no signs of disease recurrance.
• With enough tumor histology specimens (non-cytology) for molecular marker analysis.
• hemoglobin concentration ≥ 100 g/L (permit to maintain hematologic criteria by blood transfusion); absolute neutrophil count (ANC) ≥1.5×10^9/L; platelet count ≥100×10^9/L.
• Liver Function: TBil ≤2xULN; ALT and AST ≤2.5xULN;
• Renal Function: Cr ≤1.5xULN, and Ccr ≥60ml/min;
• Signed inform consent form by patient or his/her legal representative.
• Comply with study protocol and procedure, and be able to take oral medication.
• Female patients of childbearing potential must have a negative urine pregnancy test within 7 days before study treatment.
• Eligible patients of reproductive potential (both sexes) must agree to use a reliable method of birth control before enrollment, during the study period and for at least 8 weeks after their last dose of study therapy.

Exclusion Criteria

• Having targeted medication therapy (including tyrosine kinase inhibitor or monoclonal antibody) and experimental therapy for NSCLC in the past.
• Having local radiotherapy of NSCLC.
• Known allergy to Ensatinib or any of the ingredients in this product.
• Previously suffering from interstitial lung disease, drug-induced interstitial disease, radiation pneumonia that requires hormone therapy, or any clinically evidenced active interstitial lung disease; CT scan at baseline revealed the presence of idiopathic pulmonary fibrosis.
• Any unstable systemic disease, including: active infection, uncontrolled high blood pressure, unstable angina pectoris, angina pectoris that started within the last 3 months, congestive heart failure (≥ New York Heart Association [NYHA] II Grade), myocardial infarction (6 months before enrollment), severe arrhythmia requiring medical treatment; liver, kidney or metabolic diseases.
• Women who are pregnant or breastfeeding.
• Having history of neurological or psychiatric disorders, including epilepsy or dementia.
• Other conditions investigators evaluate that patient is not eligible to this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hebei Medical University Fourth Hospital

OTHER

Sponsor Role: lead

Responsible Party

LiuJunFeng

Director of thoracic surgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Jun Feng Liu

Shijiazhuang, Hebei, China

Site Status: RECRUITING

Countries

China

Central Contacts

Junfeng Liu, PhD

Role: CONTACT

liujf@hbmu.edu

13931152296

Facility Contacts

Jun Feng Liu, PhD

Role: primary

13931152296

Other Identifiers

BD-EN-IV006

Identifier Type: -

Identifier Source: org_study_id